Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value products for
gene expression analysis, today announced the launch of its miRCURY LNA™
microRNA Family Inhibitors for efficient inactivation of microRNA families.

The new miRCURY LNA™ microRNA Family Inhibitors enable researchers to
inactivate the biological function of entire microRNA families in just one
experiment. The new LNA™ enabled products offered exclusively by Exiqon will
allow scientists to save time and cost and at the same time conduct more robust
experiments than previously possible.

Exiqon's microRNA Family Inhibitors inactivate all microRNAs within a given
microRNA family using only a single or a few LNA™ enhanced oligonucleotides.
The required amount of oligonucleotide can be kept at a non-toxic level, as
each inhibitor targets more than one microRNA. In addition, LNA™ increases the
binding affinity and the biological stability of the oligonucleotides.

The new miRCURY LNA™ microRNA Family Inhibitors are short antisense
oligonucleotide targeting primarily the microRNA seed sequences conserved among
members of a specific microRNA family. It is well acknowledged that the seed
sequence has an essential role in the initial binding to the mRNAs.

In a comment, Senior Vice President Sales & Marketing, Henrik M. Pfundheller
said: “The miRCURY LNA™ microRNA Family Inhibitors meet a strong demand from
our customers and has already been tested at a number of beta-test sites
resulting in an overwhelming positive feedback. The new product enables faster
progress of functional analysis of microRNAs”. Henrik Pfundheller continues:
“The new product offering builds on 6 years of customer experience with our
miRCURY LNA™ microRNA Inhibitors, which makes me optimistic about the market
potential for our new miRCURY LNA™ microRNA Family Inhibitors”.

All microRNAs are categorized in families according to sequence homology and
biological function. The miRCURY LNA™ microRNA Family Inhibitors are available
for all the major human microRNA families.

More information about the miRCURY LNA™ microRNA Family Inhibitors products is
available at Exiqon's website: http://www.exiqon.com/

Additional information:

Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)

See the full press release in the attached PDF or at
www.exiqon.com/investor/portal.

PressRelease_Oct2011_Inhibitors.pdf